Outcomes of Reduced Frequency Dosing of Ibrutinib in Chronic Lymphocytic Leukemia Patients Following Complete or Partial Remission: A Pilot Study

BACKGROUND: Ibrutinib is a Bruton’s tyrosine kinase inhibitor that has shown to be a superior choice in the treatment of chronic lymphocytic leukemia (CLL) and a simple, oral alternative to other chemoimmunotherapies. The standard dose is 420 mg daily; however, its irreversible binding mechanism all...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexander, William, Davis, Sarah, Ramakrishna, Raj, Manoharan, Arumugam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430861/
https://www.ncbi.nlm.nih.gov/pubmed/32855753
http://dx.doi.org/10.14740/jh676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430861/
https://www.ncbi.nlm.nih.gov/pubmed/32855753
http://dx.doi.org/10.14740/jh676

Ejemplares similares